Who Should We Hire Next to Unlock Growth in Healthtech / Digital Health?
Direct answer: In healthtech, your next hire should close the biggest gap between your current stage and your next growth constraint — usually one of three roles: a regulatory/quality leader (if compliance is blocking market access), a commercial leader who understands the payer/provider buying cycle (if you have product but slow revenue), or a clinical/data science lead (if adoption depends on proving outcomes). Use McKinsey 7S to diagnose which constraint is real before you write a job description, because in digital health the wrong senior hire can burn 12–18 months you don't have.
Percision (the strategic intelligence platform behind this blog) exists to run exactly this kind of diagnosis quickly — but the framework below works whether you use software, a consultant, or a whiteboard.
Why "who to hire" is a systems question, not a headcount question
Founders usually frame the next hire as a gap: "We need a VP of Sales." But in healthtech the binding constraint is rarely the obvious one. You might not sell slowly because you lack a salesperson — you might sell slowly because your product can't clear a hospital's security review, or because you have no reimbursement pathway, or because your two clinical champions are also your only implementation team.
McKinsey 7S forces you to look at the whole system before you spend a senior salary. The seven elements — Strategy, Structure, Systems, Shared Values, Style, Staff, Skills — must be aligned. Your next hire is the person who resolves the largest misalignment, not the loudest need.
Walking McKinsey 7S through a digital health company
Work through the seven elements in order. For each, ask the honest question and define what "good" looks like at your stage.
1. Strategy. Are we selling to payers, providers, employers, or direct-to-patient — and is that decided? Healthtech go-to-market channels demand completely different hires. Good looks like: one primary buyer named, with a stated theory of why they pay you. If your strategy is still "all of the above," your next hire is arguably a commercial strategist, not a rep.
2. Structure. Who owns regulatory, clinical, and revenue outcomes today? Many digital health teams have a founder wearing all three hats. Good looks like: clear single-threaded ownership of each. A structural void here often points to your next hire directly.
3. Systems. Can we onboard a customer, stay HIPAA-compliant, and prove outcomes without heroics? Look at your implementation, security, and data pipelines. Good looks like: repeatable onboarding and audit-ready compliance. Broken systems here favor a quality/security or implementation lead over a growth hire.
4. Shared Values. Is "clinical rigor" a real operating value or a slogan? In healthtech, culture around patient safety and evidence determines what talent you can attract and retain. Good looks like: values that visibly govern trade-offs, not just the deck.
5. Style. How does leadership actually make decisions — evidence-led or founder-instinct? A senior clinical or data hire will collide with an instinct-driven culture. Good looks like: a decision style your next hire can survive in.
6. Staff. Where is the team stretched to breaking? Map who is doing two jobs. Good looks like: a clear list of the roles held together by a single overloaded person.
7. Skills. What capability do we structurally lack — not just miss on a bad week? Distinguish a temporary gap (hire a contractor) from a missing muscle (hire a leader). Good looks like: a named capability the org will need for the next 18 months and cannot borrow.
The hire to make next sits where Strategy, Structure, and Skills point to the same missing element. When Structure shows no regulatory owner, Strategy requires FDA clearance, and Skills confirms no one can run a QMS — that's your hire, and it's not a salesperson.
Turning the diagnosis into a hiring decision
Once you've scored the seven elements, force a ranking: which single misalignment, if unresolved, stops the next fundraise or milestone? That misalignment defines the role, the seniority, and the first 90 days.
Then pressure-test the reverse: if we hire this person and everything goes right, does growth actually unlock — or does a second constraint immediately bind? If a great VP of Sales still can't sell because you have no reimbursement code, the sales hire is premature. The 7S map exposes these sequencing traps before the offer letter.
Where Percision fits — and where it doesn't
Percision helps when you want a structured, board-ready version of this analysis fast. You feed in your business context, and it runs the situation through 27+ frameworks (including 7S) across 83 reasoning steps to produce a prioritized diagnosis, scenario analysis for different hiring sequences, and an execution plan you can put in front of your board or investors — in minutes rather than an 8–12 week engagement. It's a co-pilot: your leadership team still owns the final call. Broader research supports the pattern — for example, a Harvard Business School / BCG field experiment ("Navigating the Jagged Technological Frontier," 2023) found consultants using generative AI completed tasks faster and at higher quality on suitable problems. Diagnostic framing is one of those suitable problems.
A human consultant is better when the decision is politically sensitive (replacing a founder-level role), when you need someone in the room to manage board dynamics, or when the analysis depends on deep, relationship-specific knowledge of your payer contracts.
A spreadsheet is enough when the answer is already obvious — you have one screaming constraint, a clear budget, and no real disagreement on the team. Don't buy a platform to confirm what everyone already knows.
If you want to run the 7S diagnosis and get a prioritized hiring recommendation you can defend to your board, you can try Percision here.
What this looks like when the analysis is actually run
The first phase hires nobody, and that is the point — the constraint is a contract template, not headcount.
The subject is Vantabridge Health, a sample company profile we use for testing rather than a customer: a virtual chronic-care platform, $62M revenue, 340,000 enrolled members.
Excerpt from a real Percision run · Cost Reduction (T7) · sample company profile
Phase 1, months 0–6. Existing team only — legal, finance, account management. The General Counsel and VP Finance draft the new contract template; the VP Finance models the impact across the 8 contracts up for Q4 2026 renewal; the Chief Revenue Officer briefs the 34 health-plan account teams. Each action carries $0 of investment.
Phase 2, months 6–18. Existing team plus 2 additional account managers, funded within the $14M annual burn. Account Management Directors run renegotiation on the 8 renewals; the VP Data Science tracks outcome-prediction accuracy on the 10k cohort against the 75% threshold; the VP Finance monitors PMPM erosion signals.
Phase 3, months 18–36. Scale-up to 130 FTE — 116 clinical and 14 business development — if the gates are met, with a VP Business Development running a $1.5M data licensing pilot and a VP Product running a $2.0M reinsurance analytics pilot with 3–5 carrier partners, both funded from improved EBITDA.
The separate commercial hire. 2 FTE employer specialists at $180K fully loaded over 18 months, returning 13.0×.
| Assumption | Probability |
|---|---|
| Health plans accept 25% downside cap without demanding 15-20% PMPM reduction to compensate | 0.7 |
| Outcome-prediction accuracy (currently 75% on 10k cohort) remains stable during contract transition | 0.8 |
| 34 contracts renew at 80%+ rate even with reduced downside exposure | 0.75 |
Two account managers and two employer specialists is the entire near-term hiring plan for a company at $62M of ARR. Everything else is conditional on gates — the 116-clinical, 14-business-development structure only exists if 80% of the 34 contracts renew at the cap and the licensing pilot reaches $500K of ARR.
The VP Data Science assignment is the one most companies would skip. Tracking prediction accuracy on the 10k cohort is not a growth activity; it is the early-warning system for a renegotiation strategy that stops being honest the moment accuracy drops below 70%.
Read a complete Percision report — every page, no email required.
FAQ
Should a seed-stage digital health startup hire a regulatory lead before a sales leader? It depends on your strategy element. If market access is gated by FDA clearance or a reimbursement pathway, regulatory/clinical ownership usually precedes commercial hiring — selling before you can be reimbursed wastes the sales hire's ramp.
How is McKinsey 7S better than just listing open roles? A role list captures symptoms; 7S captures the system. It reveals when a "sales problem" is actually a systems or structure problem, preventing an expensive mis-hire that won't move growth.
Can Percision replace our recruiter or head of talent? No. It informs which role and why — the strategic diagnosis and sequencing. Sourcing, assessing, and closing candidates remain human work.
Disclosure: This article is published by Percision (percision.app), a strategic intelligence platform. We aim to present it honestly as one option among consultants and manual analysis.